SynBiotic SE
XETRA SBX.DE
SynBiotic SE Operating Cash Flow for the year ending December 31, 2023: USD -3.23 M
SynBiotic SE Operating Cash Flow is USD -3.23 M for the year ending December 31, 2023, a 56.88% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
-
SynBiotic SE Operating Cash Flow for the year ending December 31, 2022 was USD -7.48 M, a -27.82% change year over year.
-
SynBiotic SE Operating Cash Flow for the year ending December 31, 2021 was USD -5.86 M, a -279.44% change year over year.
-
SynBiotic SE Operating Cash Flow for the year ending December 31, 2020 was USD -1.54 M.
Key data
| Date | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid |
|---|
Market news
Loading...
XETRA: SBX.DE
| CEO | Mr. Daniel Kruse |
| IPO Date | Jan. 7, 2021 |
| Location | Germany |
| Headquarters | Innere Wiener Str. 14 |
| Employees | 55 |
| Sector | Health Care |
| Industries | |
Description
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email